Shanghai RAAS Hits Day Low of CNY 4.80 Amid Price Pressure

Shanghai RAAS Blood Products Co., Ltd. experienced a notable decline today, with the stock dropping by 4.17% and reaching an intraday low of CNY 4.80. This performance is part of a broader trend, as the company has faced challenges over the past year, with a significant decline of 30.75% compared to the China Shanghai Composite's increase of 3.56%. In terms of financial metrics, the company has reported a net profit of CNY 443.85 million, reflecting a substantial decrease of 51.84%. Additionally, the operating cash flow has reached a low of CNY -686.81 million, indicating ongoing financial strain. Over the last five years, net sales have grown at an annual rate of 18.93%, while operating profit has only increased by 5.81%. The stock's performance over various time frames shows a consistent underperformance against the China Shanghai Composite, with declines of 23.97% year-to-date and 31.44% over the past three years. With a market capitalization of CNY 33,354 million, Shanghai RAAS Blood Products operates within the pharmaceuticals and biotechnology sector, but its recent financial results highlight significant challenges ahead.